Latest news and press releases about Elicio Therapeutics, Inc. (ELTX): earnings reports, analyst upgrades/downgrades, product launches, partnerships and regulatory filings. Stay updated on every market-moving event.
Elicio Therapeutics, Inc. is a clinical-stage biotechnology firm dedicated to creating a diverse array of innovative immunotherapies for the treatment of various cancers and other diseases. The company's primary experimental drug, ELI-002, is an AMP therapeutic vaccine specifically formulated to target KRAS-driven cancers.
Price
| Price | $1.77 |
| Market Cap | $34M |
| Exchange | NASDAQ |
| Country | US |
Valuation Ratios
| Price / Book | 3.91 |
| EV / EBITDA | -0.90 |
| Dividend Yield | 0.00% |
Profitability
| Return on Equity | -1266.43% |
| Return on Invested Capital | -163.43% |
| Return on Assets | -120.78% |
| Gross Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Related companies: ACTU · APLT · CRBP · CRDF · MIST · MOLN · NKTX
Explore sector: Healthcare · Biotechnology
More sections of ELTX: Overview · Financials · Valuation · Statistics · Estimates · Technical · Ownership · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks